In humans, however, only people carrying certain mutations in hepatic genes (PNPLA3, PYGO1, TM6SF2, and HSD17B13) will develop NAFLD, as these mutations disrupt TG mobilisation and secretion, leading to fat accumulation28. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.